March 1, 2018

Nemaura Announces Expansion of Manufacturing Capabilities for SugarBEAT® Commercial Launch

LOUGHBOROUGH, England–(BUSINESS WIRE)–Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced it has commenced expansion into new manufacturing facilities, enabling large scale production of its proprietary sensor technology.

Nemaura recently reported positive results for its European sugarBEAT® trials, and, in preparation for commercial launch, has initiated scale-up manufacture of the various sugarBEAT® components alongside facilities for final assembly and packaging. As part of this process, Nemaura has expanded its manufacturing and assembly capabilities by occupying additional space within Nemaura’s existing headquarters site at Loughborough Science Park in the UK. This expansion is expected to enable Nemaura to meet anticipated demand arising from the planned sugarBEAT® launch in the UK, Europe, Middle East and Australia.

SugarBEAT® is expected to launch initially in the UK upon achieving CE approval, which is anticipated in the coming months. Additional US clinical studies to facilitate FDA clearance are expected to commence in the second quarter, with further studies expected thereafter for the use of sugarBEAT® in critical care settings.

About Nemaura Medical, Inc.

Nemaura Medical Inc. (NASDAQ: NMRD), is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose monitoring system for adjunctive use by persons with diabetes. SugarBEAT® consists of a disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings. For more information, please visit and

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts, and may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Nemaura Medical’s ongoing studies, including the safety and efficacy of Nemaura Medical’s sugarBEAT® system, the failure of future development and preliminary marketing efforts, Nemaura Medical’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura Medical and its partners’ ability to develop, market and sell sugarBEAT®, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to sugarBEAT®. These and other risks and uncertainties are identified and described in more detail in Nemaura Medical’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the current year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura Medical undertakes no obligation to publicly update or revise any forward-looking statements.


Nemaura Medical
Bashir Timol
Director of Strategy & Corporate Development